Rivela envisions a world in which a simple blood test will be sufficient for the early detection of multiple cancers, enabling routine identification of tumours in asymptomatic patients and, ultimately, improving disease outcomes and people’s quality of life.
Rivela's liquid biopsy technology enables the earliest possible identification of tumours
Rivela is aiming to make all this available globally through standard laboratory techniques, avoiding the need for complex Next-Gen Sequencing, at a price point that revolutionises access to life-saving cancer interventions, whoever you are or where you live. By achieving this goal, we will reduce the devastating impact of the rise of global cancer rates and improve the lives of those affected by the disease.
This site uses anonymous technical and statistical cookies, necessary for its operation.
These cookies cannot be disabled as they are necessary for the site to operate.
Technical cookies that do not profile the user in any way for advertising purposes and are not shared with third parties.